PubMed:2528969 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":1034,"end":1040},"obj":"HP_0002018"},{"id":"T2","span":{"begin":1048,"end":1055},"obj":"HP_0012378"},{"id":"T3","span":{"begin":1066,"end":1074},"obj":"HP_0002315"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"bc5cdr-valid-experiment","denotations":[{"id":"T1","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T2","span":{"begin":114,"end":128},"obj":"Chemical"},{"id":"T3","span":{"begin":199,"end":209},"obj":"Chemical"},{"id":"T4","span":{"begin":460,"end":471},"obj":"Disease"},{"id":"T5","span":{"begin":541,"end":551},"obj":"Chemical"},{"id":"T6","span":{"begin":1034,"end":1040},"obj":"Disease"},{"id":"T7","span":{"begin":1048,"end":1055},"obj":"Disease"},{"id":"T8","span":{"begin":1066,"end":1074},"obj":"Disease"},{"id":"T9","span":{"begin":1714,"end":1729},"obj":"Disease"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"bc5cdr-valid-deepseek-nr-ng-experiment","denotations":[{"id":"T1","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T2","span":{"begin":199,"end":209},"obj":"Chemical"},{"id":"T3","span":{"begin":331,"end":334},"obj":"Disease"},{"id":"T4","span":{"begin":541,"end":551},"obj":"Chemical"},{"id":"T5","span":{"begin":1714,"end":1729},"obj":"Disease"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"bc5cdr-valid-deepseek-nr-g-experiment","denotations":[{"id":"T1","span":{"begin":0,"end":6},"obj":"Chemical"},{"id":"T2","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T3","span":{"begin":199,"end":209},"obj":"Chemical"},{"id":"T4","span":{"begin":331,"end":334},"obj":"Disease"},{"id":"T5","span":{"begin":541,"end":551},"obj":"Chemical"},{"id":"T6","span":{"begin":1034,"end":1040},"obj":"Disease"},{"id":"T7","span":{"begin":1048,"end":1055},"obj":"Disease"},{"id":"T8","span":{"begin":1066,"end":1074},"obj":"Disease"},{"id":"T9","span":{"begin":1175,"end":1185},"obj":"Chemical"},{"id":"T10","span":{"begin":1318,"end":1338},"obj":"Chemical"},{"id":"T11","span":{"begin":1351,"end":1367},"obj":"Chemical"},{"id":"T12","span":{"begin":1383,"end":1400},"obj":"Chemical"},{"id":"T13","span":{"begin":1528,"end":1546},"obj":"Chemical"},{"id":"T14","span":{"begin":1658,"end":1669},"obj":"Disease"},{"id":"T15","span":{"begin":1714,"end":1729},"obj":"Disease"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"bc5cdr-valid-gpt-r-ng-experiment","denotations":[{"id":"T1","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T2","span":{"begin":114,"end":128},"obj":"Chemical"},{"id":"T3","span":{"begin":199,"end":209},"obj":"Chemical"},{"id":"T4","span":{"begin":331,"end":343},"obj":"Disease"},{"id":"T5","span":{"begin":460,"end":471},"obj":"Disease"},{"id":"T6","span":{"begin":541,"end":551},"obj":"Chemical"},{"id":"T7","span":{"begin":1034,"end":1040},"obj":"Disease"},{"id":"T8","span":{"begin":1048,"end":1055},"obj":"Disease"},{"id":"T9","span":{"begin":1066,"end":1074},"obj":"Disease"},{"id":"T10","span":{"begin":1175,"end":1185},"obj":"Chemical"},{"id":"T11","span":{"begin":1714,"end":1729},"obj":"Disease"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"bc5cdr-valid-gpt-r-g-experiment","denotations":[{"id":"T1","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T2","span":{"begin":62,"end":74},"obj":"Disease"},{"id":"T3","span":{"begin":114,"end":128},"obj":"Chemical"},{"id":"T4","span":{"begin":199,"end":209},"obj":"Chemical"},{"id":"T5","span":{"begin":218,"end":230},"obj":"Disease"},{"id":"T6","span":{"begin":331,"end":334},"obj":"Disease"},{"id":"T7","span":{"begin":460,"end":463},"obj":"Disease"},{"id":"T8","span":{"begin":541,"end":551},"obj":"Chemical"},{"id":"T9","span":{"begin":971,"end":986},"obj":"Disease"},{"id":"T10","span":{"begin":1034,"end":1040},"obj":"Disease"},{"id":"T11","span":{"begin":1048,"end":1055},"obj":"Disease"},{"id":"T12","span":{"begin":1066,"end":1074},"obj":"Disease"},{"id":"T13","span":{"begin":1714,"end":1729},"obj":"Disease"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"bc5cdr-valid-gpt-r-m30","denotations":[{"id":"T1","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T2","span":{"begin":62,"end":74},"obj":"Disease"},{"id":"T3","span":{"begin":114,"end":128},"obj":"Chemical"},{"id":"T4","span":{"begin":199,"end":209},"obj":"Chemical"},{"id":"T5","span":{"begin":218,"end":230},"obj":"Disease"},{"id":"T6","span":{"begin":331,"end":343},"obj":"Disease"},{"id":"T7","span":{"begin":460,"end":471},"obj":"Disease"},{"id":"T8","span":{"begin":541,"end":551},"obj":"Chemical"},{"id":"T9","span":{"begin":971,"end":986},"obj":"Disease"},{"id":"T10","span":{"begin":1034,"end":1040},"obj":"Disease"},{"id":"T11","span":{"begin":1048,"end":1055},"obj":"Disease"},{"id":"T12","span":{"begin":1066,"end":1074},"obj":"Disease"},{"id":"T13","span":{"begin":1714,"end":1729},"obj":"Disease"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"bc5cdr-valid-gpt-r-m20","denotations":[{"id":"T1","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T2","span":{"begin":62,"end":74},"obj":"Disease"},{"id":"T3","span":{"begin":114,"end":128},"obj":"Chemical"},{"id":"T4","span":{"begin":199,"end":209},"obj":"Chemical"},{"id":"T5","span":{"begin":218,"end":230},"obj":"Disease"},{"id":"T6","span":{"begin":331,"end":343},"obj":"Disease"},{"id":"T7","span":{"begin":460,"end":471},"obj":"Disease"},{"id":"T8","span":{"begin":541,"end":551},"obj":"Chemical"},{"id":"T9","span":{"begin":971,"end":986},"obj":"Disease"},{"id":"T10","span":{"begin":1034,"end":1040},"obj":"Disease"},{"id":"T11","span":{"begin":1048,"end":1055},"obj":"Disease"},{"id":"T12","span":{"begin":1066,"end":1074},"obj":"Disease"},{"id":"T13","span":{"begin":1714,"end":1729},"obj":"Disease"}],"text":"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.\nTo characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)"}